Inspira Technologies HYLA Blood Sensor Achieves 96% Accuracy in Study
Ticker: IINNW · Form: 6-K · Filed: Mar 4, 2025 · CIK: 1837493
Sentiment: bullish
Topics: medical-device, clinical-trial, accuracy-results
TL;DR
Inspira's HYLA Blood Sensor hit 96% accuracy in a clinical study, big news for their medtech.
AI Summary
Inspira Technologies Oxy B.H.N. Ltd. announced on March 4, 2025, positive results from a clinical study of its HYLA Blood Sensor. The study demonstrated a 96% accuracy rate in detecting blood, a significant advancement for the company's medical device technology.
Why It Matters
This high accuracy rate for the HYLA Blood Sensor could lead to improved diagnostic capabilities and patient care in medical settings.
Risk Assessment
Risk Level: medium — Clinical study results are positive but require further regulatory approval and market adoption to confirm commercial success.
Key Numbers
- 96% — HYLA Blood Sensor Accuracy (Demonstrated accuracy in clinical study)
Key Players & Entities
- Inspira Technologies Oxy B.H.N. Ltd. (company) — Registrant
- HYLA Blood Sensor (product) — Device under study
- March 4, 2025 (date) — Announcement date
- 96% (percentage) — Accuracy rate
FAQ
What specific medical conditions or applications was the HYLA Blood Sensor tested for in the clinical study?
The provided filing does not specify the exact medical conditions or applications for which the HYLA Blood Sensor was tested in the clinical study.
When does Inspira Technologies expect to seek regulatory approval for the HYLA Blood Sensor based on these results?
The filing does not provide a timeline for seeking regulatory approval for the HYLA Blood Sensor.
What is the next step for the HYLA Blood Sensor after these positive clinical study results?
The filing indicates that a press release was issued, but does not detail the immediate next steps for the HYLA Blood Sensor.
Were there any adverse events reported during the clinical study of the HYLA Blood Sensor?
The press release summary furnished in the 6-K does not mention any adverse events from the clinical study.
What is the total number of participants in the clinical study for the HYLA Blood Sensor?
The filing does not disclose the number of participants in the clinical study.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 4, 2025 regarding Inspira Technologies OXY B.H.N. Ltd (IINNW).